- Our Doctors
- Dr Peter Dickinson
Dr Peter Dickinson
Consultant Clincial Oncologist
BMedSci, BM BS, MSc, MRCP, FRCR
Languages spoken
English
Expert in
Lung cancer, mesothelioma, oligometastatic disease, stereotactic radiotherapy
Overview
Centres
Specialises in
Treatments
A leading specialist in the treatment of lung cancer, and the use of Stereotactic ablative radiotherapy (SABR) to treat metastatic cancer.
Dr Peter Dickinson has worked at Leeds Teaching Hospitals NHS Trust since 2013 and joined GenesisCare in 2023 as a Specialist Advisor to its Stereotactic Ablative Radiotherapy Clinical Reference Group.
He graduated from the University of Nottingham Medical School. He completed his training in Clinical Oncology in Nottingham and a technical radiotherapy fellowship at the Christie Hospital, Manchester. Dr Dickinson was appointed as consultant at Leeds Teaching Hospitals Trust in 2013. He was Clinical Lead for Clinical Oncology at Leeds Teaching Hospitals for two years and prior to this was Clinical Lead for Radiotherapy for six years. He is a member of Royal College of Radiologists Clinical Oncology Professional Practice Board
Dr Dickinson specialises in the use of Stereotactic Radiotherapy and in the treatment of thoracic malignancies with radiotherapy and systemic therapy. He uses Stereotactic radiotherapy to treat primary lung cancer and metastases in the following areas – spine, lung, lymph node, liver, bone and adrenal gland. He uses stereotactic radiotherapy to treat metastases in areas of the body which have been treated with radiotherapy previously.
Guided by the latest evidence, Dr Dickinson tailers treatment plans to meet each patient’s individual needs and circumstances. He is an effective communicator, takes time to answer patient’s questions, and ensures that patients fully understand their treatment plan and the aims of treatment.
Dr Dickinson has an active interest in clinical research and is Principle Investigator and Sub Investigator on a number of lung cancer clinical trials.
Meet Dr Peter Dickinson
Book an appointment
I’m available for private consultations. If you have any concerns, don't hesitate to get in touch.
Professional memberships
- MRCP – Member of the Royal College of Physicians
- FRCR – Fellow of the Royal College of Radiologists
- Member of Royal College of Radiologists Clinical Oncology Professional Support and Standards Board
Private cancer treatment
Dr Dickinson treats patients with lung cancer and metastatic disease, offering personalised care using advanced radiotherapy techniques. He specialises in MRI-guided stereotactic radiotherapy delivered on the MR Linac, which can target tumours close to critical organs and safely treat areas that have previously been treated with radiotherapy.
Other treatments provided
Published research
Moreno-Olmedo E, Murray D, George B, Bassett P, Gaya A, Ezhil V, Mukherjee S, Muirhead R, Sundareyan R, Dickinson P, Good J, Owczarczyk K, Daily adaptive MR-guided stereotactic ablative re-irradiation (re-SABR) in oligometastatic liver disease: A single-institution retrospective analysis. Clinical and Translational Radiation Oncology. In Press. https://doi.org/10.1016/j.ctro.2025.101082
Moreno-Olmedo E, Owczarczyk K, Chadwick E, Dickinson P, Duffton A, Jones B, Good JS, McDonald F, Murray LJ, Rackley T, Robinson M, Sinclair J, Strawson-Smith T, Tree A, Tsang YM, Zarkar A, Dean C, Díez P, Williams M, Andratschke N, Muirhead R. Pelvic stereotactic ablative body radiotherapy (SABR) reirradiation: UK SABR consortium guidance for use in routine clinical care. Tech Innov Patient Support Radiat Oncol. 2025 Aug 5;35:100326. DOI https://doi.org/10.1016/j.tipsro.2025.100326
Moreno-Olmedo, E, George B, Woolf D, Conibear J, Gaya A, Owczarczyk K, Anzar L, Adams J, Ezhil V, Sevitt T, Dickinson P, Franks K, Martin A, Camilleri P, Good J, Hiley C, et al. MR-Guided Adaptive Stereotactic Ablative Body Radiotherapy (MRgSABR) in Thoracic Tumours.” Lung Cancer, vol. 190, 107700, 2024, https://doi.org/10.1016/j.lungcan.2024.107700
Moreno-Olmedo, E., Owczarczyk, K., Murray, D., George, B., Gaya, A., Ezhil, V., Sundareyan, R., Mukherjee, S., Dickinson, P., & Good, J. (2025). 1780 Clinical and dosimetric outcomes of Stereotactic MR-guided adaptive radiotherapy (SMART) reirradiation for Liver Metastases. Radiotherapy and Oncology, 206, S1778–S1780. https://doi.org/10.1016/S0167-8140(25)00647-4
Seddon B, Grange FL, Simões R, Stacey C, Shelly S, Forsyth S, White L, Candish C, Dickinson P, Miah A, Moinuddin SA, Wylie J, Lopes A. The IMRiS Trial: A Phase 2 Study of Intensity Modulated Radiation Therapy in Extremity Soft Tissue Sarcoma. Int J Radiat Oncol Biol Phys. 2024 Nov 15;120(4):978-989. https://doi.org/10.1016/j.ijrobp.2024.05.024. Epub 2024 Jun 10.
Slevin F, Aitken K, Alongi F, Arcangeli S, Chadwick E, Chang AR, Cheung P, Crane C, Guckenberger M, Jereczek-Fossa BA, Kamran SC, Kinj R, Loi M, Mahadevan A, Massaccesi M, Mendez LC, Muirhead R, Pasquier D, Pontoriero A, Spratt DE, Tsang YM, Zelefsky MJ, Lilley J, Dickinson P, Hawkins MA, Henry AM, Murray LJ. An international Delphi consensus for pelvic stereotactic ablative radiotherapy re-irradiation. Radiother Oncol. 2021 Nov;164:104-114. DOI https://doi.org/10.1016/j.radonc.2021.09.010 Epub 2021 Sep 21.
Chalkidou A, Macmillan T, Grzeda MT, Peacock J, Summers J, Eddy S, Coker B, Patrick H, Powell H, Berry L, Webster G, Ostler P, Dickinson PD, Hatton MQ, Henry A, Keevil S, Hawkins MA, Slevin N, van As N. Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol. 2021 Jan;22(1):98-106. DOI https://doi.org/10.1016/S1470-2045(20)30537-4
GMC Registration
GMC reference number: 6101671
When I first meet patients in clinic, they’ve often recently received a cancer diagnosis and are understandably frightened and anxious about what they’ve been told. I take time to ensure they understand the information they have been told, and I’m always happy to discuss a patient’s questions and concerns. I’m passionate about being at the cutting edge of cancer care and learning about new radiotherapy and systemic therapy treatments so I can make those available to my patients.
- Dr Peter Dickinson